AvenCell Therapeutics
CompanyUnited States· Biotech
Cell therapy company developing allogeneic CAR-T therapies.
Minutes holds 1 development and 1 deal naming AvenCell Therapeutics, recorded from September 2026.
Intelligence
Investors in rounds covered by Minutes
Deals in Minutes
| Company | Deal | Amount | Counterparties | Date ↓ | Status |
|---|---|---|---|---|---|
| AvenCell TherapeuticsBiotech | FundingRoyalty financing plus Series C | Up to $47M | Investors Ligand Pharmaceuticals | 24 Sep | Announced |
- AvenCell TherapeuticsUp to $47MFundingRoyalty financing plus Series C, with Ligand PharmaceuticalsBiotech · 24 Sep · Announced